FDA Clearance Tracker · P950027-S009
HYALGAN
Last checked: Nov 20, 2026Latest source record: May 1, 2008 (this decision)Source: openFDAMethods & limitations
Decided
May 1, 2008
Approved
Time to decision
316 days
Received Jun 20, 2007. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P950027-S009
- Device name
- HYALGAN
- Applicant
- Fidia Farmaceutici S.P.A.
- Applicant location
- Abano Terme
- Received
- Jun 20, 2007
- Decided
- May 1, 2008
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P950027
Device type
- Device type
- Acid, hyaluronic, intraarticular (MOZ)
- Device class
- Class III
- Specialty
- Orthopedic Surgery
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE MODIFICATION OF THE MANUFACTURING PROCESS FOR HYALGAN FOR PRODUCING HYALURONATE BY A BACTERIAL FERMENTATION AND IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NONPHARMACOLOGIC THERAPY, AND TO SIMPLE ANALGESICS, E.G., ACETAMINOPHEN.
Source documents
Other decisions for Fidia Farmaceutici S.P.A.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K191052 · Decided Jan 9, 2020 · 265 days after receipt
Device type: Lubricant, Personal (NUC) · Obstetrics & Gynecology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.